In the past week, PSTV stock has gone down by -72.02%, with a monthly decline of -75.63% and a quarterly plunge of -76.02%. The volatility ratio for the week is 55.66%, and the volatility levels for the last 30 days are 19.13% for Plus Therapeutics Inc The simple moving average for the last 20 days is -71.46% for PSTV stock, with a simple moving average of -79.43% for the last 200 days.
Is It Worth Investing in Plus Therapeutics Inc (NASDAQ: PSTV) Right Now?
Additionally, the 36-month beta value for PSTV is 0.89. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PSTV is 5.75M and currently, short sellers hold a 1.04% ratio of that float. The average trading volume of PSTV on March 05, 2025 was 76.63K shares.
PSTV) stock’s latest price update
The stock of Plus Therapeutics Inc (NASDAQ: PSTV) has decreased by -54.21 when compared to last closing price of 0.66. Despite this, the company has experienced a -72.02% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-04 that HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H.
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with Ladenburg Thalmann repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on January 25, 2021 of the previous year 2021.
Maxim Group, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $6. The rating they have provided for PSTV stocks is “Buy” according to the report published on October 16th, 2020.
PSTV Trading at -73.16% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.68% of loss for the given period.
Volatility was left at 19.13%, however, over the last 30 days, the volatility rate increased by 55.66%, as shares sank -75.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -71.76% lower at present.
During the last 5 trading sessions, PSTV fell by -72.02%, which changed the moving average for the period of 200-days by -86.07% in comparison to the 20-day moving average, which settled at $1.0589. In addition, Plus Therapeutics Inc saw -73.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PSTV starting from Hawkins Richard J, who purchase 4,000 shares at the price of $1.50 back on Sep 13 ’24. After this action, Hawkins Richard J now owns 15,188 shares of Plus Therapeutics Inc, valued at $5,996 using the latest closing price.
Hawkins Richard J, the Director of Plus Therapeutics Inc, purchase 6,285 shares at $1.35 during a trade that took place back on Sep 12 ’24, which means that Hawkins Richard J is holding 11,188 shares at $8,512 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.26 for the gross margin
The net margin for Plus Therapeutics Inc stands at -3.02. The total capital return value is set at 2.85. Equity return is now at value -522.50, with -127.22 for asset returns.
Based on Plus Therapeutics Inc (PSTV), the company’s capital structure generated -1.92 points at debt to capital in total, while cash flow to debt ratio is standing at -3.3. The debt to equity ratio resting at -0.66. The interest coverage ratio of the stock is -3.93.
Currently, EBITDA for the company is -12.69 million with net debt to EBITDA at -0.18. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.44.
Conclusion
In conclusion, Plus Therapeutics Inc (PSTV) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
